NFE2L1 showed high expression in esophageal carcinoma, lymphoid neoplasm, diffuse large B-cell lymphoma, pancreatic adenocarcinoma, and thymoma, while low expression in uterine corpus endometrial carcinoma, ovarian serous cystadenocarcinoma, and uterine carcinosarcoma analyzed by GEPIA web server (http://gepia.cancer-pku.cn/detail.php?gene=NFE2L1). This evidence concerns the gene NFE2L1 and carcinoma of esophagus.